The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Zarochentseva N.V.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Belaia Iu.M.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Dzhidzhikhiia L.K.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Vaccinal prevention of cervical cancer and diseases associated with human papillomavirus: questions and answers

Authors:

Zarochentseva N.V., Belaia Iu.M., Dzhidzhikhiia L.K.

More about the authors

Read: 3582 times


To cite this article:

Zarochentseva NV, Belaia IuM, Dzhidzhikhiia LK. Vaccinal prevention of cervical cancer and diseases associated with human papillomavirus: questions and answers. Russian Bulletin of Obstetrician-Gynecologist. 2017;17(5):23‑28. (In Russ.)
https://doi.org/10.17116/rosakush201717523-28

Recommended articles:
Modern treatment of patients with cervical cancer. Russian Bulletin of Obstetrician-Gynecologist. 2025;(6):29-36

References:

  1. Kaprin AD, Starinsky VV, Petrova GV. Malignant neoplasms in Russia in 2014 Morbidity and mortality. Moscow: MNIOI P.A. Herzen. 2015;245. (In Russ.)
  2. Barnarck JL, Reddy DM, Swain C. Predictors of patients willingness to vaccinate for human papillomavirus and physicians intentions to recommend the vaccine. Womens Health Issues. 2010;20:1:28-34.
  3. Malignant neoplasms in Russia in 2015, the Morbidity and mortality. Eds. Kaprin AD, Starinskii VV, Petrova VG. Moscow: FGBU MNIOI. Herzen. 2016;236. (In Russ.)
  4. Walboomers JM, Jacobs MV, Manos MM, Human papillomavirus is a necessary case of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
  5. Bosch FX, Lorinez A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:4:244-265.
  6. Sanjose S. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncology. 2010;11:1048-1056.
  7. Alemany L, de Sanjose S, Tous S, Quint W. Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007. Int J Cancer. 2014;135:1:88-95.
  8. Weekly epidemiological Bulletin of the WHO. Vaccines against human papillomavirus infection human: the document at the position WHO. 2014;43:89:465-492. (In Russ.)
  9. Dochez C, Bogers JJ, Verhelst R, Rees H. HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine. 2014;32:1595-1601.
  10. Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modeling study. Lancet Global Health. 2014;2:7:406.
  11. Paul L. Drugs Tetravalent recombinant vaccine against human papillomavirus (types 6, 11, 16, 18) (Gardasil): an analysis of the use for the prevention of precancerous rectal lesions, cervical cancer, cancer of the anal canal and genital warts. 2014;74:1253-1283.
  12. Roden R. Preventative and therapeutic vaccines for cervical cancer. Exp Rev Vaccines. 2003;2:495-516.
  13. Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, Sings HL, Perez G, Haupt RM, Saah AJ, Lievano F, Velicer C, Drury R, Kuter BJ. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J. 2015;34:9:983-991.
  14. Gee J, Naleway A, Shui I. Monitoring the of quadrivalent human papillomavirus vaccine: findings from the vaccine safety datalink. Vaccine. 2011;29:46:8279-8284.
  15. World Health Organization. Global advisory committee on vaccine safety, 12—13 June 2013: update on human papillomavirus vaccines. Wkly Epidemiol Rec. 2013;88:29:309-312.
  16. World Health Organization. Global advisory committee on vaccine safety, 11-12 December 2013: human papillomavirus vaccines safety. Wkly Epidemiol Rec. 2014;89:7:58-60.
  17. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum Vaccin. 2009;5:5.
  18. Suzanne M, Kevin A, Stanley A, Heather L, Karen L, Alfred S. Pregnancy outcomes and outcomes in children in clinical studies of vaccines against human papillomavirus 6, 11, 16 and 18-th types. Obstet Gynecol. 2009;6:114.
  19. Castellsague X, Munoz N, Pitisuttithum P. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011;105:1:28-37.
  20. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25:2:215-222.
  21. Joura EA, Garland SM, Paavonen J. Effect of the human papillomavirus quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial date. BMJ. 2012;344:1401.
  22. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN II—III)? Gynecol Oncol. 2013;130: 2:264-268.
  23. Protasov AD, Lipatov IS, Kostinov MP, Tezikov YuV, Shmit`ko AD, Pakhomov DV, Blagovidov DA, Zhestkov AV, Ryzhov AA, Vekhova EV. Anogenital warts: a new way of solving the common problem of urology (resalrs of long-term follow-up). Urologiya. 2016;5:47-51. (In Russ.)
  24. Erickson BK, Landers EE, Huh WK. Update on vaccination clinical trials for HPV-related disease. Clinic Ther. 2014;36:1:8-16.
  25. Naud PS, Roteli-Martins CM, De Carvaiho NS. Sustained efficacy, immunogenicity and safety of the HPV-16/18 ASO4 adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Human Vaccine and Immunotherapeuthics. 2014;10:8.
  26. Ferris D, Samakoses R, Block SL. Long Term Study of a quadrivalent Human Papilloma. Virus Vaccine Pediatrics. 2014;134:657-665.
  27. Bonanni P, Cohet C, Kjaer SK. A summary of the postlicensure surveillance initiatives for Gardasil/Sigard. Vaccine. 2010;28:30: 4719-4730.
  28. IARC. Planning and Developing Population-Based Cancer Registration in Low and Middle-Income Settings. http: //www.iarc.fr/en/publications/pdfs-online/treport-pub/treport-pub43/index.php
  29. Goldie SJ. Projected clinical benefits and cost-effecriveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96: 604-615.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.